|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacac M and Stamenkovic I: Metastatic
cancer cell. Annu Rev Pathol. 3:221–247. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singletary SE and Connolly JL: Breast
cancer staging: Working with the sixth edition of the AJCC cancer
staging manual. CA Cancer Clin. 56:37–47. 2006. View Article : Google Scholar
|
|
4
|
Adachi Y and Yanagida M: Higher order
chromosome structure is affected by cold-sensitive mutations in a
Schizosaccharomyces pombe gene crm1+ which encodes a 115-kD protein
preferentially localized in the nucleus and its periphery. J Cell
Biol. 108:1195–1207. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Turner JG, Dawson J and Sullivan DM:
Nuclear export of proteins and drug resistance in cancer. Biochem
Pharmacol. 83:1021–1032. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fukuda M, Asano S, Nakamura T, Adachi M,
Yoshida M, Yanagida M and Nishida E: CRM1 is responsible for
intracellular transport mediated by the nuclear export signal.
Nature. 390:308–311. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arnaoutov A, Azuma Y, Ribbeck K, Joseph J,
Boyarchuk Y, Karpova T, McNally J and Dasso M: Crm1 is a mitotic
effector of Ran-GTP in somatic cells. Nat Cell Biol. 7:626–632.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vancurova I and Vancura A: Regulation and
function of nuclear IκBα in inflammation and cancer. Am J Clin Exp
Immunol. 1:56–66. 2012.PubMed/NCBI
|
|
9
|
Fornerod M, Ohno M, Yoshida M and Mattaj
IW: CRM1 is an export receptor for leucine-rich nuclear export
signals. Cell. 90:1051–1060. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brodie KM and Henderson BR:
Characterization of BRCA1 protein targeting, dynamics, and function
at the centrosome: A role for the nuclear export signal, CRM1, and
Aurora A kinase. J Biol Chem. 287:7701–7716. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chan KS, Wong CH, Huang YF and Li HY:
Survivin withdrawal by nuclear export failure as a physiological
switch to commit cells to apoptosis. Cell Death Dis. 1:e572010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mariano AR, Colombo E, Luzi L, Martinelli
P, Volorio S, Bernard L, Meani N, Bergomas R, Alcalay M and Pelicci
PG: Cytoplasmic localization of NPM in myeloid leukemias is
dictated by gain-of-function mutations that create a functional
nuclear export signal. Oncogene. 25:4376–4380. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Henderson BR: Nuclear-cytoplasmic
shuttling of APC regulates beta-catenin subcellular localization
and turnover. Nat Cell Biol. 2:653–660. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cunningham MA, Zhu Q and Hammond JM:
FoxO1a can alter cell cycle progression by regulating the nuclear
localization of p27kip in granulosa cells. Mol Endocrinol.
18:1756–1767. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Swamy MV, Herzog CR and Rao CV: Inhibition
of COX-2 in colon cancer cell lines by celecoxib increases the
nuclear localization of active p53. Cancer Res. 63:5239–5242.
2003.PubMed/NCBI
|
|
16
|
Rexhepaj R, Rotte A, Gu S, Michael D,
Pasham V, Wang K, Kempe DS, Ackermann TF, Brücher B, Fend F, et al:
Tumor suppressor gene adenomatous polyposis coli downregulates
intestinal transport. Pflugers Arch. 461:527–536. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meens MJ, Sabine A, Petrova TV and Kwak
BR: Connexins in lymphatic vessel physiology and disease. FEBS
Lett. 588:1271–1277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Moura MB, dos Santos LS and Van Houten
B: Mitochondrial dysfunction in neurodegenerative diseases and
cancer. Environ Mol Mutagen. 51:391–405. 2010.PubMed/NCBI
|
|
19
|
Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH
and Sun YJ: Prognostic value of CRM1 in pancreas cancer. Clin
Invest Med. 32:E3152009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang S, Han X, Wang J, Yao J and Shi Y:
Antitumor effects of a novel chromosome region maintenance 1 (CRM1)
inhibitor on non-small cell lung cancer cells in vitro and in mouse
tumor xenografts. PloS One. 9:e898482014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Manning L, O'Rourke KI, Knowles DP, Marsh
SA, Spencer YI, Moffat E, Wells GA and Czub S: A collaborative
Canadian-United Kingdom evaluation of an immunohistochemistry
protocol to diagnose bovine spongiform encephalopathy. J Vet Diagn
Invest. 20:504–508. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen A, Wang Y, Zhao Y, Zou L, Sun L and
Cheng C: Expression of CRM1 in human gliomas and its significance
in p27 expression and clinical prognosis. Neurosurgery. 65:153–159.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Noske A, Weichert W, Niesporek S, Röske A,
Buckendahl AC, Koch I, Sehouli J, Dietel M and Denkert C:
Expression of the nuclear export protein chromosomal region
maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian
cancer. Cancer. 112:1733–1743. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van der Watt PJ, Maske CP, Hendricks DT,
Parker MI, Denny L, Govender D, Birrer MJ and Leaner VD: The
Karyopherin proteins, crm1 and karyopherin beta1, are overexpressed
in cervical cancer and are critical for cancer cell survival and
proliferation. Int J Cancer. 124:1829–1840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang X, Cheng L, Yao L, Ren H, Zhang S,
Min X, Chen X, Zhang J and Li M: Involvement of chromosome region
maintenance 1 (CRM1) in the formation and progression of esophageal
squamous cell carcinoma. Med Oncol. 31:1552014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Inoue H, Kauffman M, Shacham S, Landesman
Y, Yang J, Evans CP and Weiss RH: CRM1 blockade by selective
inhibitors of nuclear export attenuates kidney cancer growth. J
Urol. 189:2317–2326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kojima K, Kornblau SM, Ruvolo V, Dilip A,
Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, et al:
Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
Blood. 121:4166–4174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou F, Qiu W, Yao R, Xiang J, Sun X, Liu
S, Lv J and Yue L: CRM1 is a novel independent prognostic factor
for the poor prognosis of gastric carcinomas. Med Oncol.
30:7262013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun X, Qiu J, Qi W, Liu J, Liang J and Qiu
W: Expression of CRM1 and Her-2/neu and their clinical significance
in gastric cancer. Cancer Cell Res. 1:27–36:. 2014.
|
|
31
|
Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen
P, Sun YJ, Tang LN and Zheng SE: The expression of CRM1 is
associated with prognosis in human osteosarcoma. Oncol Rep.
21:229–235. 2009.PubMed/NCBI
|
|
32
|
Zheng Y, Gery S, Sun H, Shacham S,
Kauffman M and Koeffler HP: KPT-330 inhibitor of XPO1-mediated
nuclear export has anti-proliferative activity in hepatocellular
carcinoma. Cancer Chemother Pharmacol. 74:487–495. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gravina GL, Tortoreto M, Mancini A, Addis
A, Di Cesare E, Lenzi A, Landesman Y, McCauley D, Kauffman M,
Shacham S, et al: XPO1/CRM1-selective inhibitors of nuclear export
(SINE) reduce tumor spreading and improve overall survival in
preclinical models of prostate cancer (PCa). J Hematol Oncol.
7:462014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kudo N, Matsumori N, Taoka H, Fujiwara D,
Schreiner EP, Wolff B, Yoshida M and Horinouchi S: Leptomycin B
inactivates CRM1/exportin 1 by covalent modification at a cysteine
residue in the central conserved region. Proc Natl Acad Sci USA.
96:9112–9117. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Parikh K, Cang S, Sekhri A and Liu D:
Selective inhibitors of nuclear export (SINE)-a novel class of
anti-cancer agents. J Hematol Oncol. 7:782014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Azmi AS, Aboukameel A, Bao B, Sarkar FH,
Philip PA, Kauffman M, Shacham S and Mohammad RM: Selective
inhibitors of nuclear export block pancreatic cancer cell
proliferation and reduce tumor growth in mice. Gastroenterology.
144:447–456. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tai YT, Landesman Y, Acharya C, Calle Y,
Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, et
al: CRM1 inhibition induces tumor cell cytotoxicity and impairs
osteoclastogenesis in multiple myeloma: Molecular mechanisms and
therapeutic implications. Leukemia. 28:155–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang K, Wang M, Tamayo AT, Shacham S,
Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, et al: Novel
selective inhibitors of nuclear export CRM1 antagonists for therapy
in mantle cell lymphoma. Exp Hematol. 41:67–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lapalombella R, Sun Q, Williams K,
Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta
S, et al: Selective inhibitors of nuclear export show that
CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood.
120:4621–4634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ranganathan P, Yu X, Na C, Santhanam R,
Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M,
et al: Preclinical activity of a novel CRM1 inhibitor in acute
myeloid leukemia. Blood. 120:1765–1773. 2012. View Article : Google Scholar : PubMed/NCBI
|
